Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $78.28 in the prior trading day, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $77.77, down -0.65%. In other words, the price has decreased by -$0.65 from its previous closing price. On the day, 0.6 million shares were traded. TARS stock price reached its highest trading level at $79.77 during the session, while it also had its lowest trading level at $77.63.
Ratios:
Our goal is to gain a better understanding of TARS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.25 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $100.
On November 20, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’25 when LINK WILLIAM J PHD sold 12,500 shares for $81.43 per share. The transaction valued at 1,017,816 led to the insider holds 128,832 shares of the business.
LINK WILLIAM J PHD sold 10,446 shares of TARS for $846,862 on Dec 15 ’25. The Director now owns 0 shares after completing the transaction at $81.07 per share. On Dec 16 ’25, another insider, Lin Elizabeth Yeu, who serves as the Chief Medical Officer of the company, sold 2,078 shares for $79.50 each. As a result, the insider received 165,201 and left with 21,941 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 3301266688 and an Enterprise Value of 2981938944. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.02 while its Price-to-Book (P/B) ratio in mrq is 9.85. Its current Enterprise Value per Revenue stands at 8.145 whereas that against EBITDA is -34.832.
Stock Price History:
The Beta on a monthly basis for TARS is 0.60, which has changed by 0.50538456 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $85.25, while it has fallen to a 52-week low of $38.51. The 50-Day Moving Average of the stock is 4.31%, while the 200-Day Moving Average is calculated to be 42.62%.
Shares Statistics:
The stock has traded on average 537.66K shares per day over the past 3-months and 479950 shares per day over the last 10 days, according to various share statistics. A total of 42.45M shares are outstanding, with a floating share count of 39.12M. Insiders hold about 7.84% of the company’s shares, while institutions hold 104.83% stake in the company. Shares short for TARS as of 1764288000 were 7116863 with a Short Ratio of 13.24, compared to 1761868800 on 7279055. Therefore, it implies a Short% of Shares Outstanding of 7116863 and a Short% of Float of 17.330000000000002.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Tarsus Pharmaceuticals Inc (TARS) in the stock market.The consensus estimate for the next quarter is -$0.07, with high estimates of $0.05 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$1.34 and -$1.48 for the fiscal current year, implying an average EPS of -$1.41. EPS for the following year is $1.33, with 5.0 analysts recommending between $2.99 and $0.59.
Revenue Estimates
7 analysts predict $143.78M in revenue for. The current quarter. It ranges from a high estimate of $145.5M to a low estimate of $142.76M. As of. The current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $66.41MFor the next quarter, 7 analysts are estimating revenue of $148.6M. There is a high estimate of $155M for the next quarter, whereas the lowest estimate is $144.57M.
A total of 8 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $445.2M, while the lowest revenue estimate was $442.45M, resulting in an average revenue estimate of $443.47M. In the same quarter a year ago, actual revenue was $182.95MBased on 7 analysts’ estimates, the company’s revenue will be $679M in the next fiscal year. The high estimate is $776.67M and the low estimate is $604.3M.
